Bourgeon Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.3M Buy
24,426
+1,127
+5% +$1.15M 4.31% 2
2026
Q1
$21.4M Sell
23,299
-219
-0.9% -$222K 3.71% 3
2025
Q4
$25.3M Sell
23,518
-29
-0.1% -$27.7K 4.09% 3
2025
Q3
$18M Buy
23,547
+10,676
+83% +$7.94M 3.24% 4
2025
Q2
$10M Buy
12,871
+11,959
+1,311% +$9.29M 1.98% 24
2025
Q1
$753K Sell
912
-487
-35% -$405K 0.16% 66
2024
Q4
$1.08M Buy
+1,399
New +$1.16M 0.2% 61
2020
Q4
Sell
-5
Closed -$1K 298
2020
Q3
$1K Buy
+5
New +$774 ﹤0.01% 282

Other funds holding LLY

Bourgeon Capital Management's LLY Position: Q2 2026 in Review

Bourgeon Capital Management increased its Eli Lilly (LLY) stake by 4.8% in Q2 2026, buying an estimated $1.15M and bringing the position to 24,426 shares worth $29.3M. The position accounts for 4.31% of the portfolio, ranked #2.

Bourgeon Capital Management first reported a position in LLY in Q3 2020 and has held it in 8 quarters since. 4,623 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bourgeon Capital Management held 24,426 shares of Eli Lilly worth $29.3M as of Q2 2026.
  • Bourgeon Capital Management bought 1,127 Eli Lilly shares in Q2 2026, an estimated $1.15M.
  • Eli Lilly made up 4.31% of Bourgeon Capital Management's portfolio in Q2 2026, its #2 holding.
  • Bourgeon Capital Management first reported a position in Eli Lilly in Q3 2020 and has held it in 8 quarters since.
  • 4,623 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bourgeon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.